A Phase 2, Open-Label, Multi-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-based Chemo as Second-line Treatment, in Participants with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Principal Investigator
-
Sponsor
Janssen Research & Development
The purpose of this study is to help researchers understand more about the possible effectiveness and safety of the combination of amivantamab and lazertinib in patients with non-small cell lung cancer (NSCLC) who have a specific mutation in the EGFR (epidermal growth factor receptor) gene.
Enrollment Form
This study is currently enrolling.